PPARγ Regulates GPNMB to Promote Oligodendrocyte Maturation and Remyelination
Overview
PPARγ is identified as a key transcription factor enriched in dysfunctional oligodendrocyte precursor cells (OPCs) within CNS demyelinated lesions. Activation of PPARγ enhances OPC differentiation and remyelination by directly targeting GPNMB, a novel regulator of myelinogenesis, while PPARγ deficiency impairs these processes.
Background
Oligodendrocytes are essential for CNS myelination and are derived from OPCs. Failure of remyelination in neurological diseases is mainly due to impaired OPC differentiation rather than OPC depletion. PPARγ, a nuclear receptor known for its neuroprotective effects, has been implicated in OPC differentiation in vitro, but its in vivo role and downstream mechanisms in CNS remyelination were previously unclear. Understanding PPARγ’s regulation of OPC maturation could reveal new therapeutic targets for demyelinating diseases.
Data Highlights
Pharmacological activation of PPARγ with agonists pioglitazone and rosiglitazone significantly increased OPC differentiation and remyelination in mouse models of cuprizone- and lysophosphatidylcholine-induced demyelination. Conversely, oligodendrocyte-specific PPARγ knockout reduced OPC maturation and myelin formation, and diminished the efficacy of PPARγ agonists. RNA-seq and CUT&Tag analyses identified GPNMB as a direct PPARγ target gene promoting OPC differentiation and remyelination.
Key Findings
PPARγ expression is enriched in dysfunctional OPCs within CNS demyelinated lesions and increases during OPC differentiation and myelination.
Pharmacological activation of PPARγ promotes OPC maturation and enhances remyelination in multiple demyelination models.
Oligodendrocyte-specific knockout or inhibition of PPARγ impairs OPC differentiation and myelin generation.
PPARγ directly regulates GPNMB, which drives OPC differentiation and promotes myelinogenesis and remyelination.
PPARγ and its downstream effector GPNMB represent promising targets for regenerative therapies in CNS demyelinating diseases.
Clinical Implications
Targeting PPARγ signaling pharmacologically may enhance endogenous OPC differentiation and remyelination, offering a potential therapeutic strategy for demyelinating disorders such as multiple sclerosis. Modulation of the PPARγ-GPNMB axis could improve myelin repair and functional recovery in CNS injury. Further clinical studies are warranted to evaluate PPARγ agonists for remyelination therapy.
Conclusion
This study establishes PPARγ as a positive regulator of OPC differentiation and CNS remyelination through direct activation of GPNMB. These findings highlight PPARγ and GPNMB as novel molecular targets for promoting myelin repair in demyelinating diseases.
References
Original Article 2024 -- PPARγ Nuclear Receptor Regulates GPNMB to Enhance Oligodendrocyte Maturation and Remyelination
